Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT-Reference-Cited by-同舟云学术

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT

Published:2018-08-27 Issue:1 Volume:46 Page:139-147
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Rathke Hendrik^ORCID,Kratochwil Clemens,Hohenberger Ralph,Giesel Frederik Lars,Bruchertseifer Frank,Flechsig Paul,Morgenstern Alfred,Hein Matti,Plinkert Peter,Haberkorn Uwe,Bulut Olcay Cem

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-018-4135-8/fulltext.html

Reference35 articles.

1. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95. https://doi.org/10.1007/s00259-012-2298-2 .

2. Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169–76. https://doi.org/10.2967/jnumed.115.158550 .

3. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33. https://doi.org/10.1016/S1470-2045(18)30198-0 .

4. Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted alpha therapy of mCRPC with (225)actinium-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor-control. J Nucl Med. 2018;59(5):795–802. https://doi.org/10.2967/jnumed.117.203539 .

5. Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624–31. https://doi.org/10.2967/jnumed.117.191395 .

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Automated preparation of Actinium-225 with accelerator-based production from irradiated natural thorium targets;Separation and Purification Technology;2025-02

2. Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass;Annals of Nuclear Medicine;2024-07-26

3. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going;Cancer Treatment Reviews;2024-06

4. PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy;The Cancer Journal;2024-05

5. Preparation, Biological Evaluation, and First-in-Human Single-Photon Emission Computed Tomography (SPECT) Study of ^99mTc-Labeled Prostate-Specific Membrane Antigen (PSMA)-Targeted Radiotracers Containing Triazole with Reduced Kidneys Accumulation;ACS Pharmacology & Translational Science;2024-04-10